Kite's yescarta® only car t-cell therapy to show durable response and long-term survival after five years in patients with relapsed/refractory non-hodgkin lymphomas at ash 2024

Santa monica, calif.--(business wire)--kite, a gilead company (nasdaq: gild), today announced results from a five-year follow-up analysis of zuma-5, a phase 2 study of yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-hodgkin lymphomas (nhl) including follicular lymphoma (fl) or marginal zone lymphoma (mzl). the analysis demonstrated that after a median follow-up of more than five years, patients treated with yescarta continued to experience durable response and long-.
CAR Ratings Summary
CAR Quant Ranking